Low-Dose Aspirin Shows Promise for Preventing Colorectal Cancer Recurrence
A targeted approach using aspirin reduces recurrence risk in patients with PI3K pathway mutations
Key Takeaway
A phase 3 clinical trial revealed that daily low-dose aspirin significantly reduces colorectal cancer (CRC) recurrence in patients with specific genetic mutations in the PI3K signaling pathway.
Understanding the Study
The ALASCCA trial, presented at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, inves…
